Literature DB >> 22430874

Vasculitis of the upper airways.

Christian Pagnoux1, Nikolaus E Wolter.   

Abstract

Systemic vasculitides are rare and potentially life-threatening diseases. Granulomatosis with polyangiitis (GPA; formerly Wegener's granulomatosis) and Churg Strauss syndrome (possibly to be renamed eosinophilic granulomatosis with polyangiitis; EGPA) are the 2 chief systemic vasculitides which may involve the upper respiratory tract. Chronic allergic rhinitis and nasal polyposis in EGPA, and recurrent sinusitis and/or otitis in both conditions, are not specific and can thus represent real diagnostic challenges if they are the first manifestations of the disease. Nasal septum perforation, saddle nose deformity and/or subglottic stenosis (SGS), although not totally specific, are more suggestive of GPA. Because upper airway manifestations often tend to be refractory to systemic therapy and/or to linger, local treatment represents a major aspect of management of the condition, especially for patients with SGS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22430874     DOI: 10.4414/smw.2012.13541

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  10 in total

Review 1.  [Laboratory diagnostics for early detection of rheumatic autoimmune diseases: a guide for the general practitioner].

Authors:  Georg Endler; Ulrike Demel; Ernst Forster; Andrea Griesmacher; Christin Hübner; Werner Klotz; Günter Steiner; W Wagner; Manfred Herold
Journal:  Wien Med Wochenschr       Date:  2012-08-14

Review 2.  Granuloma in ANCA-associated vasculitides: another reason to distinguish between syndromes?

Authors:  Antje Mueller; Konstanze Holl-Ulrich; Wolfgang L Gross
Journal:  Curr Rheumatol Rep       Date:  2013-11       Impact factor: 4.592

3.  [Manifestation of eosinophilic granulomatosis with polyangiitis in the head and neck area over time taking systemic disease activity into consideration].

Authors:  Henrik Andersen; Paul Götz; Jan Phillip Bremer; Martin Laudien
Journal:  Z Rheumatol       Date:  2018-12       Impact factor: 1.372

4.  Identifying relevant determinants of in-hospital time to diagnosis for ANCA-associated vasculitis patients.

Authors:  Ebru Dirikgil; Sander W Tas; Cornelis A Verburgh; Darius Soonawala; A Elisabeth Hak; Hilde H F Remmelts; Daphne IJpelaar; Gozewijn D Laverman; Abraham Rutgers; Jaap M van Laar; Hein J Bernelot Moens; Peter M J Verhoeven; Ton J Rabelink; Willem Jan W Bos; Y K Onno Teng
Journal:  Rheumatol Adv Pract       Date:  2022-06-09

Review 5.  The role of surgery in antineutrophil cytoplasmic antibody-associated vasculitides affecting the nose and sinuses: A systematic review.

Authors:  Alfonso Luca Pendolino; Samit Unadkat; Henry Zhang; Monica Pendolino; Gerolamo Bianchi; Premjit S Randhawa; Peter J Andrews
Journal:  SAGE Open Med       Date:  2020-07-01

6.  Sinonasal involvement in systemic vasculitides and cocaine-induced midline destructive lesions: Diagnostic controversies.

Authors:  M Armengot; A García-Lliberós; M J Gómez; A Navarro; A Martorell
Journal:  Allergy Rhinol (Providence)       Date:  2013

7.  Extracorporeal membrane oxygenation rescue in adolescent with bronchiolitis obliterans-organizing pneumonia like Wegener's granulomatosis.

Authors:  Lars Falk; Lars Mikael Broman
Journal:  Clin Case Rep       Date:  2016-12-17

8.  Autoimmune-related nasal septum perforation: A case report and systematic review.

Authors:  Lohitha Guntupalli; Kunjan Patel; Farhoud Faraji; Joseph D Brunworth
Journal:  Allergy Rhinol (Providence)       Date:  2017-03-01

9.  Erosive rhinitis resembling granulomatosis with polyangiitis (Wegener's granulomatosis) in an Anatolian shepherd dog.

Authors:  Marlies Böhm; Sandra Basson
Journal:  J S Afr Vet Assoc       Date:  2015-04-21       Impact factor: 1.474

10.  ANCA-negative Wegener's granulomatosis with multiple lower cranial nerve palsies.

Authors:  Sung-Hee Kim; Jin Park; Jung Ho Bae; Min-Sun Cho; Kee Duk Park; Jee Hyang Jeong
Journal:  J Korean Med Sci       Date:  2013-10-31       Impact factor: 2.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.